I have just heard that both the appraisal for dasatinib; nilotinib; HD-imatainb in IM resistant CML will now be combined with appraisal for dasatinib;nilotinib in IM intolerant CML. The committee have obviously revised their original decision to separate intolerance from resistance and revert to the original scope: they will publish one single FAD covering their recommendations for both groups of patients.
I thought I would share this with you so that those of you who are planning a holiday over the next couple of weeks can do so without worrying that you will miss anything.
CMLSg will be notified on 18th July- but I will be away on holiday from Tuesday 12th until Tuesday 26th July.- however I will try to access my emails on the 18th.
We will then have 15 working days to appeal, should the FAD be negative.
However, to appeal a FAD is more complex than commenting on an ACD.
Please note: the appraisal is now called:
'Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (part review TA70) and dasatinib and nilotinib for people with chronic myeloid leukaemia for whom treatment with imatinib has failed because of intolerance'
The FAD will be released to consultees and commentators in the week commencing 18 July.
It will be available to the public on a new page for the above named appraisal on the NICE website http://www.nice.org.uk/guidance/index.jsp?action=byID&o=13501 five working days following that....i.e Monday 25th July
Sandy